Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis

Sebastian M. Gygli, Peter M. Keller, Marie Ballif, Nicolas Blöchliger, Rico Hömke, Miriam Reinhard, Chloé Loiseau, Claudia Ritter, Peter Sander, Sonia Borrell, Jimena Collantes Loo, Anchalee Avihingsanon, Joachim Gnokoro, Marcel Yotebieng, Matthias Egger, Sebastien Gagneux, Erik C. Böttger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Whole-genome sequencing allows rapid detection of drug-resistant Mycobacterium tuberculosis isolates. However, the availability of high-quality data linking quantitative phenotypic drug susceptibility testing (DST) and genomic data have thus far been limited. We determined drug resistance profiles of 176 genetically diverse clinical M. tuberculosis isolates from the Democratic Republic of the Congo, Ivory Coast, Peru, Thailand, and Switzerland by quantitative phenotypic DST for 11 antituberculous drugs using the BD Bactec MGIT 960 system and 7H10 agar dilution to generate a cross-validated phenotypic DST readout. We compared DST results with predicted drug resistance profiles inferred by whole-genome sequencing. Classification of strains by the two phenotypic DST methods into resistotype/wild-type populations was concordant in 73 to 99% of cases, depending on the drug. Our data suggest that the established critical concentration (5 mg/liter) for ethambutol resistance (MGIT 960 system) is too high and mis-classifies strains as susceptible, unlike 7H10 agar dilution. Increased minimal inhibitory concentrations were explained by mutations identified by whole-genome sequencing. Using whole-genome sequences, we were able to predict quantitative drug resistance levels for the majority of drug resistance mutations. Predicting quantitative levels of drug resistance by whole-genome sequencing was partially limited due to incompletely understood drug resistance mechanisms. The overall sensitivity and specificity of whole-genome-based DST were 86.8% and 94.5%, respectively. Despite some limitations, whole-genome sequencing has the potential to infer resistance profiles without the need for time-consuming phenotypic methods.

Original languageEnglish (US)
Article numbere02175-18
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number4
DOIs
StatePublished - Apr 2019
Externally publishedYes

Fingerprint

Mycobacterium tuberculosis
Drug Resistance
Genome
Pharmaceutical Preparations
Agar
Cote d'Ivoire
Democratic Republic of the Congo
Ethambutol
Multidrug-Resistant Tuberculosis
Mutation
Peru
Thailand
Switzerland
Sensitivity and Specificity
Population

Keywords

  • Drug resistance
  • Drug resistance level prediction
  • Mycobacterium tuberculosis
  • Quantitative phenotypic drug susceptibility testing
  • Whole-genome sequencing

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Gygli, S. M., Keller, P. M., Ballif, M., Blöchliger, N., Hömke, R., Reinhard, M., ... Böttger, E. C. (2019). Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 63(4), [e02175-18]. https://doi.org/10.1128/AAC.02175-18

Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. / Gygli, Sebastian M.; Keller, Peter M.; Ballif, Marie; Blöchliger, Nicolas; Hömke, Rico; Reinhard, Miriam; Loiseau, Chloé; Ritter, Claudia; Sander, Peter; Borrell, Sonia; Loo, Jimena Collantes; Avihingsanon, Anchalee; Gnokoro, Joachim; Yotebieng, Marcel; Egger, Matthias; Gagneux, Sebastien; Böttger, Erik C.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 4, e02175-18, 04.2019.

Research output: Contribution to journalArticle

Gygli, SM, Keller, PM, Ballif, M, Blöchliger, N, Hömke, R, Reinhard, M, Loiseau, C, Ritter, C, Sander, P, Borrell, S, Loo, JC, Avihingsanon, A, Gnokoro, J, Yotebieng, M, Egger, M, Gagneux, S & Böttger, EC 2019, 'Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy, vol. 63, no. 4, e02175-18. https://doi.org/10.1128/AAC.02175-18
Gygli, Sebastian M. ; Keller, Peter M. ; Ballif, Marie ; Blöchliger, Nicolas ; Hömke, Rico ; Reinhard, Miriam ; Loiseau, Chloé ; Ritter, Claudia ; Sander, Peter ; Borrell, Sonia ; Loo, Jimena Collantes ; Avihingsanon, Anchalee ; Gnokoro, Joachim ; Yotebieng, Marcel ; Egger, Matthias ; Gagneux, Sebastien ; Böttger, Erik C. / Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 4.
@article{1c021354359f4d42a63ca202d5296041,
title = "Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis",
abstract = "Whole-genome sequencing allows rapid detection of drug-resistant Mycobacterium tuberculosis isolates. However, the availability of high-quality data linking quantitative phenotypic drug susceptibility testing (DST) and genomic data have thus far been limited. We determined drug resistance profiles of 176 genetically diverse clinical M. tuberculosis isolates from the Democratic Republic of the Congo, Ivory Coast, Peru, Thailand, and Switzerland by quantitative phenotypic DST for 11 antituberculous drugs using the BD Bactec MGIT 960 system and 7H10 agar dilution to generate a cross-validated phenotypic DST readout. We compared DST results with predicted drug resistance profiles inferred by whole-genome sequencing. Classification of strains by the two phenotypic DST methods into resistotype/wild-type populations was concordant in 73 to 99{\%} of cases, depending on the drug. Our data suggest that the established critical concentration (5 mg/liter) for ethambutol resistance (MGIT 960 system) is too high and mis-classifies strains as susceptible, unlike 7H10 agar dilution. Increased minimal inhibitory concentrations were explained by mutations identified by whole-genome sequencing. Using whole-genome sequences, we were able to predict quantitative drug resistance levels for the majority of drug resistance mutations. Predicting quantitative levels of drug resistance by whole-genome sequencing was partially limited due to incompletely understood drug resistance mechanisms. The overall sensitivity and specificity of whole-genome-based DST were 86.8{\%} and 94.5{\%}, respectively. Despite some limitations, whole-genome sequencing has the potential to infer resistance profiles without the need for time-consuming phenotypic methods.",
keywords = "Drug resistance, Drug resistance level prediction, Mycobacterium tuberculosis, Quantitative phenotypic drug susceptibility testing, Whole-genome sequencing",
author = "Gygli, {Sebastian M.} and Keller, {Peter M.} and Marie Ballif and Nicolas Bl{\"o}chliger and Rico H{\"o}mke and Miriam Reinhard and Chlo{\'e} Loiseau and Claudia Ritter and Peter Sander and Sonia Borrell and Loo, {Jimena Collantes} and Anchalee Avihingsanon and Joachim Gnokoro and Marcel Yotebieng and Matthias Egger and Sebastien Gagneux and B{\"o}ttger, {Erik C.}",
year = "2019",
month = "4",
doi = "10.1128/AAC.02175-18",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis

AU - Gygli, Sebastian M.

AU - Keller, Peter M.

AU - Ballif, Marie

AU - Blöchliger, Nicolas

AU - Hömke, Rico

AU - Reinhard, Miriam

AU - Loiseau, Chloé

AU - Ritter, Claudia

AU - Sander, Peter

AU - Borrell, Sonia

AU - Loo, Jimena Collantes

AU - Avihingsanon, Anchalee

AU - Gnokoro, Joachim

AU - Yotebieng, Marcel

AU - Egger, Matthias

AU - Gagneux, Sebastien

AU - Böttger, Erik C.

PY - 2019/4

Y1 - 2019/4

N2 - Whole-genome sequencing allows rapid detection of drug-resistant Mycobacterium tuberculosis isolates. However, the availability of high-quality data linking quantitative phenotypic drug susceptibility testing (DST) and genomic data have thus far been limited. We determined drug resistance profiles of 176 genetically diverse clinical M. tuberculosis isolates from the Democratic Republic of the Congo, Ivory Coast, Peru, Thailand, and Switzerland by quantitative phenotypic DST for 11 antituberculous drugs using the BD Bactec MGIT 960 system and 7H10 agar dilution to generate a cross-validated phenotypic DST readout. We compared DST results with predicted drug resistance profiles inferred by whole-genome sequencing. Classification of strains by the two phenotypic DST methods into resistotype/wild-type populations was concordant in 73 to 99% of cases, depending on the drug. Our data suggest that the established critical concentration (5 mg/liter) for ethambutol resistance (MGIT 960 system) is too high and mis-classifies strains as susceptible, unlike 7H10 agar dilution. Increased minimal inhibitory concentrations were explained by mutations identified by whole-genome sequencing. Using whole-genome sequences, we were able to predict quantitative drug resistance levels for the majority of drug resistance mutations. Predicting quantitative levels of drug resistance by whole-genome sequencing was partially limited due to incompletely understood drug resistance mechanisms. The overall sensitivity and specificity of whole-genome-based DST were 86.8% and 94.5%, respectively. Despite some limitations, whole-genome sequencing has the potential to infer resistance profiles without the need for time-consuming phenotypic methods.

AB - Whole-genome sequencing allows rapid detection of drug-resistant Mycobacterium tuberculosis isolates. However, the availability of high-quality data linking quantitative phenotypic drug susceptibility testing (DST) and genomic data have thus far been limited. We determined drug resistance profiles of 176 genetically diverse clinical M. tuberculosis isolates from the Democratic Republic of the Congo, Ivory Coast, Peru, Thailand, and Switzerland by quantitative phenotypic DST for 11 antituberculous drugs using the BD Bactec MGIT 960 system and 7H10 agar dilution to generate a cross-validated phenotypic DST readout. We compared DST results with predicted drug resistance profiles inferred by whole-genome sequencing. Classification of strains by the two phenotypic DST methods into resistotype/wild-type populations was concordant in 73 to 99% of cases, depending on the drug. Our data suggest that the established critical concentration (5 mg/liter) for ethambutol resistance (MGIT 960 system) is too high and mis-classifies strains as susceptible, unlike 7H10 agar dilution. Increased minimal inhibitory concentrations were explained by mutations identified by whole-genome sequencing. Using whole-genome sequences, we were able to predict quantitative drug resistance levels for the majority of drug resistance mutations. Predicting quantitative levels of drug resistance by whole-genome sequencing was partially limited due to incompletely understood drug resistance mechanisms. The overall sensitivity and specificity of whole-genome-based DST were 86.8% and 94.5%, respectively. Despite some limitations, whole-genome sequencing has the potential to infer resistance profiles without the need for time-consuming phenotypic methods.

KW - Drug resistance

KW - Drug resistance level prediction

KW - Mycobacterium tuberculosis

KW - Quantitative phenotypic drug susceptibility testing

KW - Whole-genome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85063643800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063643800&partnerID=8YFLogxK

U2 - 10.1128/AAC.02175-18

DO - 10.1128/AAC.02175-18

M3 - Article

C2 - 30718257

AN - SCOPUS:85063643800

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

M1 - e02175-18

ER -